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Background. Secondary hyperparathyroidism (HPT) and ab-
normal mineral metabolism are thought to play an important
role in bone and cardiovascular disease in patients with chronic
kidney disease. Cinacalcet, a calcimimetic that modulates the
calcium-sensing receptor, reduces parathyroid hormone (PTH)
secretion and lowers serum calcium and phosphorus concen-
trations in patients with end-stage renal disease (ESRD) and
secondary HPT.
Methods. We undertook a combined analysis of safety data
(parathyroidectomy, fracture, hospitalizations, and mortality)
from 4 similarly designed randomized, double-blind, placebo-
controlled clinical trials enrolling 1184 subjects (697 cinacalcet,
487 control) with ESRD and uncontrolled secondary HPT (in-
tact PTH ≥300 pg/mL). Cinacalcet or placebo was administered
to subjects receiving standard care for hyperphosphatemia and
secondary HPT (phosphate binders and vitamin D). Relative
risks (RR) and 95% CI were calculated using proportional
hazards regression with follow-up times from 6 to 12 months.
Health-related quality-of-life (HRQOL) data were obtained
from the Medical Outcomes Study Short Form-36 (SF-36), and
the Cognitive Functioning scale from the Kidney Disease Qual-
ity of Life instrument (KDQOL-CF).
Results. Randomization to cinacalcet resulted in significant
reductions in the risk of parathyroidectomy (RR 0.07, 95% CI
0.01–0.55), fracture (RR 0.46, 95% CI 0.22–0.95), and cardio-
vascular hospitalization (RR 0.61, 95% CI 0.43–0.86) compared
with placebo. Changes in HRQOL favored cinacalcet, with sig-
nificant changes observed for the SF-36 Physical Component
Summary score and the specific domains of Bodily Pain and
General Health Perception.
Conclusion. Combining results from 4 clinical trials, random-
ization to cinacalcet led to significant reductions in the risk
of parathyroidectomy, fracture, and cardiovascular hospitaliza-
tion, along with improvements in self-reported physical func-
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tion and diminished pain. These data suggest that, in addition
to its effects on PTH and mineral metabolism, cinacalcet had
favorable effects on important clinical outcomes.
Secondary hyperparathyroidism (HPT) is a frequent
component of the natural progression of chronic kidney
disease (CKD), typically developing when the glomeru-
lar filtration rate (GFR) drops below approximately
80 mL/min/1.73m2 for ≥3 months [1]. Secondary HPT
is an adaptive response to CKD and arises from dis-
ruptions in the homeostatic control of serum calcium,
serum phosphorus, and vitamin D, which are associated
with CKD. Characteristic skeletal features of secondary
HPT include increased bone turnover with abnormally
high rates of bone resorption, often accompanied by
bone pain and fractures [2–6]. Extraskeletal manifesta-
tions of secondary HPT include vascular calcification,
hypertension, anemia with erythropoietin resistance, pru-
ritus, and sexual dysfunction [7–14]. Conventional ther-
apy for secondary HPT can contribute to hypercalcemia
and hyperphosphatemia [15–17], laboratory abnormali-
ties associated with mortality in end-stage renal disease
(ESRD) [18–21]. We have recently demonstrated higher
risks of cardiovascular disease and fracture associated
with hyperphosphatemia and secondary HPT [19].
Vitamin D sterols are frequently used to control sec-
ondary HPT and have been shown to be effective in
suppressing parathyroid hormone (PTH) [22–24] and
improving bone histology [22, 25]. Despite the use of
vitamin D, a large fraction of ESRD patients have refrac-
tory HPT [21]. Moreover, vitamin D enhances intestinal
absorption of calcium and phosphorus, complicating the
management of mineral metabolism [26]. Cinacalcet HCl
is a calcimimetic agent that binds the calcium-sensing re-
ceptor (CaR) of the parathyroid gland, resulting in dimin-
ished PTH secretion [27]. Cinacalcet acts by allosterically
modulating the CaR, enhancing the sensitivity of the CaR
to extracellular calcium and, thus, exerting a suppressive
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effect on PTH secretion [27]. Several published studies
have demonstrated the efficacy of cinacalcet compared
with placebo in lowering PTH concentrations in ESRD
patients with secondary HPT [28–31]. In contrast with
vitamin D, when using cinacalcet the reduction in PTH
secretion has been accompanied by simultaneous reduc-
tion of the calcium×phosphorus product (Ca×P), serum
calcium, and phosphorus [28–30].
The phase 2 and phase 3 studies comparing cinacal-
cet with placebo administered to subjects receiving stan-
dard care for hyperphosphatemia and secondary HPT
were designed with sufficient power to answer questions
related to biochemical end points (e.g., proportion of
subjects with end-of-study PTH concentrations below
250 pg/mL or with a reduction of 30% or more from
baseline). However, these individual studies were not
designed to evaluate the effects of cinacalcet on mor-
bidity (including hospitalization and fracture), mortality,
or other outcomes believed to be related to the severity
of secondary HPT, such as physical function and health-
related quality of life (HRQOL). Data for these clinical
end points were obtained for safety evaluation in selected
phase 2 and all phase 3 clinical trials, all of which shared
similar subject inclusion and exclusion criteria and vir-
tually all basic design elements. Herein we present com-
bined results from these clinical trials.
METHODS
Study selection
We analyzed data pooled from all clinical trials inves-
tigating the approved dose range of cinacalcet (30 to
180 mg) with at least 6 months of follow-up. One
12-month phase 2 trial and 3 6-month phase 3 trials were
included. A 6-month extension trial of participants in 2
of the phase 3 studies was also included. The study de-
sign, including study drug dosing, was similar across all
studies included in this analysis and is described below.
The phase 2 trial was performed in the United States and
Europe and treated 48 subjects at 17 sites. The 3 phase 3
trials were performed in North America (63 sites with 410
subjects), Europe, and Australia (62 sites with 331 sub-
jects), and North America and Australia (60 sites with 395
subjects). The extension trial included subjects from the
first 2 phase 3 trials who completed study between June
20, 2002 and December 27, 2002. All subjects complet-
ing the initial phase 3 study during this 12-month period
were asked to continue their randomized treatment for
an additional 6-month period. Of the 504 subjects who
completed the 2 initial phase 3 trials, 266 subjects agreed
to continue in the extension study (128 in the cinacalcet
group and 138 in the control group).
Study subjects
The randomized clinical trials included in this anal-
ysis had similar inclusion and exclusion criteria. Each
required that eligible subjects were ≥18 years old, ex-
hibited an intact PTH level ≥300 pg/mL and an albumin-
corrected serum calcium ≥8.4 mg/dL, and had received
hemodialysis 3 times per week for a minimum of 1 to
3 months or peritoneal dialysis for ≥1 month. In 2 of the
phase 3 trials, intact PTH >800 pg/mL and Ca × P >70
mg2/dL2 were stratification variables. In these 2 studies,
the number of subjects with intact PTH >800 pg/mL was
limited to no more than 20% (similar to the percentage
observed in the general dialysis population), although this
limitation was not a requirement in the other trials.
Exclusion criteria included parathyroidectomy or my-
ocardial infarction within 3 to 6 months of the start
of treatment and change of vitamin D therapy within
30 days of the start of treatment. Additional exclusion
criteria included the use of flecainide, lithium, thori-
dazine, haloperidol, or tricyclic antidepressant (except for
amitriptyline) therapy within 21 days of the start of the
trial, gastrointestinal disturbances that could impair the
absorption of the study drug, the existence of an unstable
medical condition, and pregnancy or nursing.
The studies were approved by the Independent Ethics
Committee or the Institutional Review Board, as appro-
priate, at each study center, and were conducted in accor-
dance with the principles of the Declaration of Helsinki.
All subjects provided written informed consent.
Study design
All trials were randomized, double-blind, and placebo-
controlled. Subjects were randomized by a computer-
generated randomization system. For the 2 phase
3 studies in hemodialysis subjects, 1:1 randomization was
stratified by baseline PTH and Ca × P. For the phase 3
study enrolling hemodialysis and peritoneal dialysis sub-
jects, a 3:1 ratio (cinacalcet:placebo) was used for ran-
domization, which was stratified by dialysis modality, and
within the hemodialysis subjects by baseline PTH. The
phase 2 study utilized no stratification for the randomiza-
tion. Matching placebos were used, and the blinds were
maintained through the use of numbered study drug bot-
tles. The phase 2 study had a 24-week titration phase and
a 28-week assessment phase. The first 2 phase 3 stud-
ies used 12-week titration phases, while the third used a
16-week titration. All 3 phase 3 studies were 26 weeks
in duration, with assessment phases ranging from 10 to
14 weeks. Subjects who entered the extension portion of
the phase 3 trials received blinded treatment for an addi-
tional 26 weeks.
Subjects received cinacalcet at doses from 30 to 180 mg/
day (30, 50, 70, 90, 120, 180 mg in the phase 2 trial and
30, 60, 90, 120, 180 mg in the phase 3 and extension
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trials). These doses were titrated every 3 to 4 weeks. Sub-
jects receiving vitamin D sterols at baseline continued at
the same dose throughout the trial. Reductions in vita-
min D doses were permitted for albumin-adjusted serum
calcium ≥11 mg/dL, serum phosphorus ≥6.5 mg/dL or
Ca × P ≥70 mg2/dL2. Vitamin D doses could be increased
for serum calcium <8.4 mg/dL. Phosphate binders were
permitted, with dose changes allowed at the discretion
of the investigator. Detailed reports on the biochemical
effects and general safety of cinacalcet have been previ-
ously published [28–31].
Clinical end points
Outcomes were identified prospectively based on rea-
sons for discontinuation and adverse-event data [defined
using World Health Organization Adverse Reaction
Terminology [WHO-ART)] collected in all studies. Hos-
pitalizations were captured from the adverse event form,
with a primary preferred term (i.e., reason for hospital-
ization) provided for each event. Vital status and hos-
pitalization were assessed for an additional 30 days and
7 days, respectively, beyond the official study completion.
Follow-up time was adjusted accordingly for the analyses
shown here.
Outcomes examined include parathyroidectomy (con-
sidered a failure of therapy for secondary HPT and a
reason for study discontinuation), fracture, cardiovascu-
lar hospitalization (e.g., myocardial infarction, unstable
angina, exacerbation of heart failure), as well as all-cause
and noncardiovascular hospitalization. Reported events
were confirmed using source document verification, and
the medical records of all subjects were monitored during
the study to facilitate complete event capture.
Subject-reported outcomes
Subject-reported outcomes used in these analyses were
obtained in the phase 3 studies using touch-screen com-
puter technology (Assist Technologies, Scottsdale, AZ,
USA). Instruments used in all studies included the
Medical Outcomes Study Short Form-36 (SF-36) and the
Cognitive Functioning scale from the Kidney Disease
Quality of Life (KDQOL) instrument (KDQOL-CF).
Translated and culturally adapted versions of these in-
struments were used where appropriate. Data were col-
lected before the first dose of study drug (baseline), at
the end of the titration period, once during the middle of
the efficacy assessment phase, and at the end of the effi-
cacy assessment phase (i.e., the end of the study) for the
phase 3 studies. Change from baseline was calculated as
the difference between the baseline value and the mean
of the 2 efficacy assessment phase values. Subjects with
missing baseline data were excluded from the analyses
(N = 22), as were subjects with no values during the ef-
ficacy assessment phase (N = 238). Data from the phase
2 study were not included because subject-reported out-
comes were not assessed during the efficacy assessment
phase of the study.
Norm-based scoring was used for the SF-36, meaning
that for all scales a score of 50 represents the U.S. general
population mean, with a standard deviation of 10 points.
The KDQOL-CF was scored from 0 to 100, with a higher
score indicating better function.
Statistical analysis
Analyses were based on all randomized subjects using
an intent-to-treat approach. Cox proportional hazards
models, stratified by study, were used to make statisti-
cal comparisons for the outcomes of parathyroidectomy,
fracture, and death. The primary analyses for hospital-
izations used the Andersen-Gill model to permit multi-
ple events [32]. As the Andersen-Gill model essentially
treats the second event as independent of the first, a con-
ditional model (where the risk for a second event depends
on having experienced a first event) was also used to con-
firm the results. Relative risk (RR) estimates and 95% CIs
were calculated from model parameter coefficients and
their standard errors. Survival curves were plotted using
the time-to-event Kaplan-Meier product limit estimate.
The estimated least squares means of each of the SF-36
scale scores, as well as the KDQOL-CF score, adjusted for
study, were compared between treatment groups using t
tests. Subjects with no values either at baseline or during
the efficacy assessment phase (N = 71, 6.0%) were not
included in the analysis of the subject-reported outcomes
data. Two-tailed P values < 0.05 were considered statisti-
cally significant. All analyses were conducted using SAS
8.2 (Cary, NC, USA).
RESULTS
A total of 1184 subjects (697 cinacalcet, 487 control)
enrolled in the studies. Table 1 shows baseline character-
istics of subjects enrolled in the clinical trials. Overall, the
mean ± SD age was 53.7 ± 14.4 years; 38% were women
and 49% non-white. As expected, the median PTH was
higher in the studies with no limit on inclusion of subjects
with PTH ≥800 pg/mL. Generally, clinical characteristics
were similar across studies, and no differences in baseline
characteristics were noted among subjects enrolled in the
phase 3, 6-month extension trial and the larger popula-
tion of the 2 parent studies.
Clinical end points
Parathyroidectomy
In the cinacalcet group, there was 1 parathyroidec-
tomy in 374.2 subject-years of follow-up (0.3 parathry-
oidectomies per 100 subject-years). In the control group,
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Table 1. Baseline demographics and biochemical parameters
Cinacalcet Control Total
(N = 697) (N = 487) (N = 1184)
N (%) N (%) N (%) P value
Age
<65 years 538 (77) 348 (71) 886 (75) 0.025
≥65 years 159 (23) 139 (29) 298 (25)
Age at randomization years, mean ± SD 53.0 ± 14.2 54.7 ± 14.6 53.7 ± 14.4 0.037
Sex
Female 272 (39) 181 (37) 453 (38) 0.52
Male 425 (61) 306 (63) 731 (62)
Ethnicity
White 332 (48) 270 (55) 602 (51) 0.018
Black 265 (38) 166 (34) 431 (36)
Other 100 (14) 51 (10) 151 (13)
Dialysis modality
Hemodialysis 663 (95) 475 (98) 1138 (96) 0.034
Peritoneal dialysis 34 (5) 12 (2) 46 (4)
Vintage months, mean ± SD 65.8 ± 59.9 70.1 ± 67.1 67.6 ± 63.0 0.25
Diabetes
No 480 (69) 333 (68) 813 (69) 0.86
Yes 217 (31) 154 (32) 371 (31)
Phosphate binder use
No 49 (7) 36 (7) 85 (7) 0.81
Yes 648 (93) 451 (93) 1099 (93)
Calcium-containing only 258 (37) 200 (41) 458 (39)
Sevelamer only 211 (30) 128 (26) 339 (29)
Calcium-containing plus sevelamer 86 (12) 49 (10) 135 (11)
Other 93 (13) 74 (15) 167 (14)
Vitamin D sterol use
No 244 (35) 160 (33) 404 (34) 0.44
Naı¨ve 70 (10) 41 (8) 111 (9)
Withheld for elevated Ca, P, or Ca × P 132 (19) 86 (18) 218 (18)
Other 8 (1) 3 (1) 11 (1)
Not prescribed 30 (4) 29 (6) 59 (5)
Not indicated 4 (1) 1 (0) 5 (0)
Yes 453 (65) 327 (67) 780 (66)
Oral 180 (26) 126 (26) 306 (26)
Intravenous 234 (34) 179 (37) 413 (35)
Oral plus intravenous 4 (1) 2 (0) 6 (1)
Not indicated 35 (5) 20 (4) 55 (5)
Plasma PTH pg/mL, mean ± SD 731 ± 531 682 ± 399 711 ± 481 0.074
Serum Ca × P mg2/dL2, mean ± SD 60.9 ± 16.0 61.1 ± 15.1 61.0 ± 15.6 0.84
Serum calcium mg/dL, mean ± SD 9.9 ± 0.8 9.9 ± 0.8 9.9 ± 0.8 0.26
Serum phosphorus mg/dL, mean ± SD 6.2 ± 1.7 6.2 ± 1.5 6.2 ± 1.6 0.85
there were 12 parathyroidectomies in 294.5 subject-years
of follow-up (4.1 parathyroidectomies per 100 subject-
years) (Table 2). The RR of parathyroidectomy was much
lower (93% reduction) for the cinacalcet group (RR 0.07,
95% CI 0.01–0.55) (Fig. 1A). The median PTH at the time
of parathyroidectomy was 1056 (interquartile range 523–
1502).
Fractures
Fracture rates were lower in the cinacalcet group com-
pared with the control group (3.2 vs. 6.9 per 100 subject-
years) (Table 2). The RR of fractures was significantly
reduced in the cinacalcet group (RR 0.46, 95% CI 0.22–
0.95) (Table 2, Fig. 1B). In the control group, there were 7
fractures of the lower extremities (hip, femur, tibia, etc.),
and 13 other fractures (ribs and upper extremities). Cor-
responding data for the cinacalcet group were 11 fractures
of the lower extremities, and 1 other fracture, this being
equivalent to approximately half the rate observed with
placebo due to the larger number of subjects randomized
to receive cinacalcet.
Cardiovascular hospitalization
The rate of cardiovascular hospitalizations was lower
in the cinacalcet group compared with the control group
(15.0 vs. 19.7 hospitalizations per 100 subject-years)
(Table 2). Using the Andersen-Gill method, the RR
of cardiovascular hospitalization was significantly re-
duced among subjects receiving cinacalcet (RR 0.61,
95% CI 0.43–0.86) (Table 2, Fig. 1C). Results were vir-
tually identical using the conditional model (RR 0.63,
95% CI 0.44–0.90). In the control group, cardiovascular
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Table 2. Event rates by treatment group
Events per 100 subject-years
Hazard ratioa P value for
Clinical outcome Cinacalcet Control (95% CI) hazard ratio
Parathyroidectomy 0.3 4.1 0.07 (0.01–0.55) 0.009
Fracture 3.2 6.9 0.46 (0.22–0.95) 0.04
Cardiovascular hospitalization 15.0 19.7 0.61 (0.43–0.86) 0.005
All-cause hospitalization 67.0 71.0 1.03 (0.87–1.22) 0.74
Mortality 5.2 7.4 0.81 (0.45–1.45) 0.47
aPlacebo was used as the reference group.
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Fig. 1. Kaplan-Meier time-to-event plots for (A) parathyroidectomy, (C) bone fractures, (B) cardiovascular hospitalization, and (D) mortality in
subjects on cinacalcet versus control.
hospitalizations included 29 hospitalizations for ischemic
heart disease (including myocardial infarction and angina
pectoris), 19 for heart failure, 18 for arrhythmia, 7 for pe-
ripheral vascular disease, and 4 for stroke. Correspond-
ing data for the cinacalcet group were 22 hospitalizations
for ischemic heart disease, 26 for heart failure, 17 for
arrhythmia, 2 for peripheral vascular disease, and 5 for
stroke.
All-cause hospitalization
There was no significant difference in all-cause hos-
pitalizations between treatment groups (RR 1.03, 95%
CI 0.87–1.22) using the Andersen-Gill method (Table 2).
These results were confirmed with the conditional model
(RR 1.02, 95% CI 0.86–1.21). No significant differences
were observed between the treatment groups for non-
cardiovascular hospitalizations (Andersen-Gill RR 1.16,
95% CI 0.96–1.39) or for hospitalizations unrelated to
cardiovascular disease, fracture, or parathyroidectomy
(Andersen-Gill RR 1.18, 95% CI 0.98–1.42).
Mortality
The rate of mortality in the study population was 5.2
and 7.4 per 100 subject-years in the cinacalcet and con-
trol groups, respectively. This difference was not statis-
tically significant (RR 0.81, 95% CI 0.45–1.45) (Table 2,
Fig. 1D).
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Table 3. Mean baseline scores on the eight domains of the SF-36 and on the KDQOL-CF at baseline (combined phase 3 studies)
Cinacalcet Control
(N = 665) (N = 471)
HRQOL scales N Mean (SE) N Mean (SE)
SF-36
Physical Component Summary 640 39.8 (0.39) 459 40.6 (0.47)
Mental Component Summary 640 49.4 (0.43) 459 49.3 (0.51)
Physical functioning 649 38.9 (0.46) 464 39.2 (0.55)
Role Limitations—Physical 645 41.7 (0.46) 463 42.5 (0.54)
Bodily Pain 649 46.3 (0.45) 463 47.2 (0.55)
General Health Perception 647 39.0 (0.37) 462 39.9 (0.46)
Social Functioning 649 45.1 (0.43) 463 45.6 (0.51)
Vitality 648 47.9 (0.38) 464 47.9 (0.47)
Role Limitations—Emotional 647 44.6 (0.50) 462 44.1 (0.60)
Emotional Well Being 648 48.8 (0.43) 464 49.5 (0.51)
KDQOL
Cognitive functioning 647 79.7 (0.71) 464 79.4 (0.86)
Note: Higher values indicate better health status for all scales.
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Fig. 2. Differences in score changes (cinacalcet-treated minus control
subject scores) of combined phase 3 data on KDQOL-CF (CF) and
SF-36 (PCS, Physical Component Summary; MCS, Mental Compo-
nent Summary; SF-36 domains: PF, Physical Functioning; RP, Role
Limitations-Physical; BP, Bodily Pain; GH, General Health Perception;
SF, Social Functioning; VT, Vitality; RE, Role Limitations-Emotional;
MH, Mental Health). A positive score represents a greater improve-
ment with cinacalcet treatment compared to control treatment. Bars
represent 95% CI.
HRQOL and self-reported cognitive function
Mean baseline scores on the 8 domains of the SF-36
were approximately one half to one standard deviation
below the population mean and were similar between the
randomized groups (Table 3). Changes in HRQOL (base-
line to end-of-study) were consistently in favor of cinacal-
cet (Fig. 2). There were statistically significant differences
between treatment groups for the SF-36 Physical Com-
ponent Summary (PCS) score (0.5-unit improvement in
the cinacalcet group compared with 0.8-unit decrease in
the control group, P = 0.01), as well as the Bodily Pain
scale (0.6-unit improvement in the cinacalcet group com-
pared with 1.0-unit decrease in the control group, P =
0.03) and the General Health Perception scale (0.2-unit
improvement in the cinacalcet group compared with 1.0-
unit decrease in the control group, P = 0.02). A simi-
lar proportion of subjects in both groups experienced a
large decline in self-reported physical function (decrease
in PCS >5) points (21% vs. 23%, for cinacalcet and con-
trol groups, respectively, P = 0.52). However, significantly
more subjects in the cinacalcet group experienced a large
improvement in self-reported physical function (increase
in PCS >5) points (26% vs. 20%, P = 0.03).
Baseline values on the KDQOL-CF were 79.7 and 79.4
in the cinacalcet and control groups, respectively. There
were no significant differences in the mean change in
KDQOL-CF score by treatment group (+0.2 vs. −0.8 in
cinacalcet and control groups, respectively, P = 0.12).
DISCUSSION
Analyses of combined data from randomized, blinded,
placebo-controlled, 6- to 12-month studies of cinacalcet
versus standard care for secondary HPT showed statis-
tically significant and clinically meaningful reductions
in the risks of parathyroidectomy, fracture, and cardio-
vascular hospitalization. Although the individual clinical
studies were designed to assess changes in biochemi-
cal parameters and not a priori clinical end points, the
prospective and interventional nature of the combined
data lends credibility to the clinical relevance of biochem-
ical control in secondary HPT and suggests that therapy
with cinacalcet may lead to beneficial effects on clinical
outcomes.
Several mechanisms of action have been proposed that
support the findings observed in these trials. Reduction in
parathyroidectomy may be mediated through improved
control of PTH and reductions in parathyroid cell prolif-
eration and gland hyperplasia, which have been demon-
strated using cinacalcet in an animal model of secondary
HPT [33]. The reduction in fractures observed in this
study is consistent with preclinical evidence demonstrat-
ing that calcimimetics ameliorated high bone turnover
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and increased femoral cortical bone mineral density and
cortical bone strength [34, 35]. In multiple phase 2 and
phase 3 clinical trials, treatment with cinacalcet was asso-
ciated with favorable changes in the biochemical markers
of bone formation (bone-specific alkaline phosphatase)
and resorption (serum N-telopeptide), as well as im-
provement in bone turnover parameters [28, 36]. In addi-
tion, although the increased cardiovascular risk evident
in subjects with end-stage renal disease is multifactoral,
this risk has been related to abnormalities of vascular
biology, including calcification and arterial stiffness [37–
40]. Elevations in serum calcium, phosphorus, and Ca ×
P are known to be independent risk factors for vascular
calcification and mortality in hemodialysis subjects [11,
19, 41]. In vitro data suggest that elevated calcium and
phosphorus concentrations play a role in the calcification
of human vascular smooth muscle cells [42]. Preliminary
evidence also demonstrates that calcimimetics do not in-
crease the arterial content of calcium and phosphorus in
vitro and may mitigate vascular calcification in uremic
rats treated with calcitriol [43, 44].
In addition to the effects on fracture and car-
diovascular hospitalization, the current analysis also
demonstrated improvements in HRQOL with statisti-
cally significant improvements in the PCS scale and Pain
and General Health Perception scales, and positive trends
in other physical health domains. Several large cohort
studies and clinical trials have linked higher scores on
the PCS with reduced mortality and morbidity [45–48].
The results of these analyses highlight the importance
of examining clinical outcomes in a disease dominated
by reliance on biochemical parameters for diagnosis and
therapeutic management. These data represent the first
examination of clinical outcomes collected from prospec-
tive, randomized, and placebo-controlled studies of any
therapy used for secondary HPT. Despite the introduc-
tion of newer vitamin D analogs and increased overall
utilization of vitamin D sterols during the past decade,
no outcomes data are available from prospective clinical
trials. Over the same time period, the increasing trend
in parathyroidectomy and fracture rates and unchanged
rates of mortality and cardiovascular morbidity empha-
size the need to examine clinical outcomes in an unbiased
manner when evaluating therapeutic interventions [49,
50].
The analyses presented here have several strengths.
The clinical trials were randomized and blinded, and
clinical characteristics were well balanced by random-
ization. Although the clinical end points for this anal-
ysis were obtained from the safety records of each
clinical trial and were not independently adjudicated,
each event was verified by review of medical records.
However, this analysis has several important limitations.
The studies were not designed to evaluate differences in
event rates. Follow-up times were relatively short; longer-
term follow-up would have increased the likelihood of
demonstrating significant treatment effects. Ascertain-
ment of less severe events (e.g., fracture not requiring
hospitalization) was likely limited, and also reduced the
power to detect treatment effects.
CONCLUSION
Despite the limitations in study design, combined data
demonstrate that cinacalcet treatment of subjects on dial-
ysis with secondary HPT resulted in improvement in
clinical outcomes, especially parathyroidectomy, fracture,
cardiovascular hospitalization, and specific components
of health-related quality of life. Future trials are required
to confirm and expand on these results.
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